Publications by authors named "R D Jewell"
Innovations in medicine have allowed children with cancer to attend school more frequently by increasing survival rates and improving access to outpatient therapies. Children with cancer still miss a significant proportion of school attendance and participation during treatment, thereby disrupting their educational experiences. "Monkey in My Chair" is a program in the United States that connects ill children with their schoolmates during illness-related absences to support their social relationships and eventual school re-entry into the school environment.
View Article and Find Full Text PDFArticle Synopsis
- Cholangiocarcinoma (CCA) has a tough stroma that makes it resistant to treatments, and lysyl oxidases (LOX) play a key role in this by increasing stromal rigidity.
- Researchers analyzed human CCA tissues and used mouse models to study the effects of a pan-lysyl oxidase inhibitor, PXS-5505, on treatment outcomes.
- Inhibition of LOX improved drug delivery and effectiveness by decreasing tumor pressure, enhancing immune response, and ultimately leading to slower tumor growth and better survival rates in treated mice.
Purpose: Niraparib is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor approved for the maintenance treatment of advanced ovarian cancer (OC). Niraparib was originally approved in recurrent OC at a fixed starting dose (FSD) of 300 mg once daily (QD). This analysis characterized the population pharmacokinetics (PK) of niraparib and evaluated the relationships between exposure, efficacy, and safety to support clinical use of an individualized dosing strategy, in which the starting dose of niraparib was adjusted based on patient characteristics to improve the benefit-risk profile.
View Article and Find Full Text PDFArticle Synopsis
- KMT2C and KMT2D are important enzymes that modify genes, with KMT2C haploinsufficiency recently linked to Kleefstra syndrome 2, a neurodevelopmental disorder (NDD) with unknown clinical details.
- A study involving 98 individuals found that most pathogenic variants in KMT2C span nearly all its exons, making variant interpretation difficult; the study also established a KMT2C DNA methylation signature for better classification of the disorder.
- Key features of KMT2C-related NDD include developmental delays, intellectual disabilities, and distinct facial characteristics, setting it apart from similar conditions like Kleefstra and Kabuki syndromes, indicating the need for its renaming and